198 related articles for article (PubMed ID: 36395068)
1. FLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation.
Li Y; Yang W; Patel RM; Casey EB; Denby E; Mendoza-Castrejon J; Rodriguez-Lopez P; Magee JA
Blood; 2023 Mar; 141(12):1442-1456. PubMed ID: 36395068
[TBL] [Abstract][Full Text] [Related]
2. Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation.
Tsitsipatis D; Jayavelu AK; Müller JP; Bauer R; Schmidt-Arras D; Mahboobi S; Schnöder TM; Heidel F; Böhmer FD
Oncotarget; 2017 Apr; 8(16):26613-26624. PubMed ID: 28460451
[TBL] [Abstract][Full Text] [Related]
3. NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.
Jayavelu AK; Müller JP; Bauer R; Böhmer SA; Lässig J; Cerny-Reiterer S; Sperr WR; Valent P; Maurer B; Moriggl R; Schröder K; Shah AM; Fischer M; Scholl S; Barth J; Oellerich T; Berg T; Serve H; Frey S; Fischer T; Heidel FH; Böhmer FD
Leukemia; 2016 Feb; 30(2):473-83. PubMed ID: 26308771
[TBL] [Abstract][Full Text] [Related]
4. Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.
Poitras JL; Heiser D; Li L; Nguyen B; Nagai K; Duffield AS; Gamper C; Small D
Oncotarget; 2016 Oct; 7(43):69124-69135. PubMed ID: 27636998
[TBL] [Abstract][Full Text] [Related]
5. A noncanonical Flt3ITD/NF-κB signaling pathway represses DAPK1 in acute myeloid leukemia.
Shanmugam R; Gade P; Wilson-Weekes A; Sayar H; Suvannasankha A; Goswami C; Li L; Gupta S; Cardoso AA; Baghdadi TA; Sargent KJ; Cripe LD; Kalvakolanu DV; Boswell HS
Clin Cancer Res; 2012 Jan; 18(2):360-369. PubMed ID: 22096027
[TBL] [Abstract][Full Text] [Related]
6. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
Elife; 2016 Nov; 5():. PubMed ID: 27879203
[TBL] [Abstract][Full Text] [Related]
7. Thymic precursor cells generate acute myeloid leukemia in NUP98-PHF23/NUP98-HOXD13 double transgenic mice.
Kundu S; Park ES; Chung YJ; Walker RL; Zhu YJ; Negi V; Meltzer PS; Aplan PD
Sci Rep; 2019 Nov; 9(1):17213. PubMed ID: 31748606
[TBL] [Abstract][Full Text] [Related]
8. Modulation of FLT3 signal transduction through cytoplasmic cysteine residues indicates the potential for redox regulation.
Böhmer A; Barz S; Schwab K; Kolbe U; Gabel A; Kirkpatrick J; Ohlenschläger O; Görlach M; Böhmer FD
Redox Biol; 2020 Jan; 28():101325. PubMed ID: 31606550
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes.
Novak RL; Harper DP; Caudell D; Slape C; Beachy SH; Aplan PD
Exp Hematol; 2012 Dec; 40(12):1016-27. PubMed ID: 22885519
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Vulnerabilities in
Uras IZ; Maurer B; Nebenfuehr S; Zojer M; Valent P; Sexl V
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544932
[TBL] [Abstract][Full Text] [Related]
11. Role of glucose metabolism in the differential antileukemic effect of melatonin on wild‑type and FLT3‑ITD mutant cells.
Puente-Moncada N; Turos-Cabal M; Sánchez-Sánchez AM; Antolín I; Herrera F; Rodriguez-Blanco J; Duarte-Olivenza C; Rodriguez C; Martín V
Oncol Rep; 2020 Jul; 44(1):293-302. PubMed ID: 32319665
[TBL] [Abstract][Full Text] [Related]
12. Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.
Greenblatt S; Li L; Slape C; Nguyen B; Novak R; Duffield A; Huso D; Desiderio S; Borowitz MJ; Aplan P; Small D
Blood; 2012 Mar; 119(12):2883-94. PubMed ID: 22323452
[TBL] [Abstract][Full Text] [Related]
13. MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
Zhang X; Li B; Yu J; Dahlström J; Tran AN; Björkholm M; Xu D
Ann Hematol; 2018 Jan; 97(1):63-72. PubMed ID: 29080039
[TBL] [Abstract][Full Text] [Related]
14. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
[TBL] [Abstract][Full Text] [Related]
15. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
[No Abstract] [Full Text] [Related]
16. Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia.
Hilger N; Mueller C; Stahl L; Mueller AM; Zoennchen B; Dluczek S; Halbich C; Wickenhauser C; Gerloff D; Wurm AA; Behre G; Kretschmer A; Fricke S
Front Immunol; 2018; 9():2408. PubMed ID: 30405611
[TBL] [Abstract][Full Text] [Related]
17. Nuclear factor of activated T-cells, NFATC1, governs FLT3
Solovey M; Wang Y; Michel C; Metzeler KH; Herold T; Göthert JR; Ellenrieder V; Hessmann E; Gattenlöhner S; Neubauer A; Pavlinic D; Benes V; Rupp O; Burchert A
J Hematol Oncol; 2019 Jul; 12(1):72. PubMed ID: 31286998
[TBL] [Abstract][Full Text] [Related]
18. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype.
Schneider F; Hoster E; Unterhalt M; Schneider S; Dufour A; Benthaus T; Mellert G; Zellmeier E; Kakadia PM; Bohlander SK; Feuring-Buske M; Buske C; Braess J; Heinecke A; Sauerland MC; Berdel WE; Büchner T; Wörmann BJ; Hiddemann W; Spiekermann K
Blood; 2012 May; 119(19):4383-6. PubMed ID: 22374696
[TBL] [Abstract][Full Text] [Related]
19. The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia.
Palmqvist L; Argiropoulos B; Pineault N; Abramovich C; Sly LM; Krystal G; Wan A; Humphries RK
Blood; 2006 Aug; 108(3):1030-6. PubMed ID: 16861351
[TBL] [Abstract][Full Text] [Related]
20. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
